Session

Medical therapy of IBD: Facts and challenges (Posters)

LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE
LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE

Medical therapy of IBD: Facts and challenges (Posters)  et al.

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

Medical therapy of IBD: Facts and challenges (Posters)  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Medical therapy of IBD: Facts and challenges (Posters)  et al.

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID
EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

Medical therapy of IBD: Facts and challenges (Posters)  et al.

PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY
PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY

Medical therapy of IBD: Facts and challenges (Posters)  et al.

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Medical therapy of IBD: Facts and challenges (Posters)  et al.

PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION
PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION

Medical therapy of IBD: Facts and challenges (Posters)  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Medical therapy of IBD: Facts and challenges (Posters)  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Medical therapy of IBD: Facts and challenges (Posters)  et al.

RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB
RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB

Medical therapy of IBD: Facts and challenges (Posters)  et al.

RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB
RISK FACTORS FOR DEVELOPMENT OF ACNE FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH UPADACITINIB

LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE
LDN-071, A NOVEL FIRST-IN-CLASS PEPTIDE-BASED PLASMINOGEN ACTIVATOR INHIBITOR 1, SIGNIFICANTLY REDUCES THE SEVERITY OF EXPERIMENTAL COLITIS IN MICE

CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION
PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID
EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY
PHARMACOKINETICS OF RECTALLY ADMINISTERED COBITOLIMOD IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A PHASE IB OPEN-LABEL STUDY

Item 1 - 20 / 20
1